HOME Top Market Reports Global Human Immunodeficiency Virus (HIV) Market (2012 2017)

Global Human Immunodeficiency Virus (HIV) Market (2012 2017)

By: marketsandmarkets.com
Publishing Date: October 2018
Report Code: UC 1697

Discount on Prebooks  

  Speak to Analyst Enquiry Before Buying Webinar
purchase report
download pdf  request for customisation


Human immunodeficiency virus (HIV) is a retrovirus which causes Acquired Immunodeficiency syndrome (AIDS) in humans, a condition where immune system fails, leading to opportunistic infections that is life threatening.

HIV infection occurs via transfer of blood, semen, vaginal fluid, pre-ejaculate, or breast milk and major routes of infection transmission are unsafe sex, contaminated needles, perinatal transmission, breast milk and infected blood products.

Key Take-Aways

Define and measure HIV therapeutic market by stages of development, market structure, strategically analyze each submarket, analyze HIV pipeline & marketed products and profile key players in the segment.

Research Methodology

Market information and pipeline analysis was obtained through secondary research on company websites, news articles and other standard paid and un-paid sources; Market size of the segments was calculated using the bottom-up approach.


  • HIV therapeutic manufacturers
  • Contract research organizations (CROs)
  • Healthcare & research institutions

Table of Contents

1. Introduction
   1.1 Key Take-aways
   1.2 Report Description
   1.3 Markets Covered
   1.4 Research Methodology
   1.5 Stakeholders

2. Summary

3. Disease Overview
   3.1 Epidemiology

4. Current Scenario
   4.1 Market by Products
       4.1.1 Key Brands
            Brand Name
            Active Ingredient
            Mechanism of action
            Dosage form (s)
            Latest Sales Figures
            Launch Date/Year
(All the above attributes under Truvada will be covered for
the brands mentioned below)
       4.1.2 Key Molecules
            Trade Name
            Active Ingredient
            Mechanism of action
            Dosage form (s)
            Latest Sales Figures
            Expected Launch Date/Year
(All the above attributes under Efavirenz will be covered for the molecules mentioned below)
   4.2 Market by Mechanism of Action (MOA)
       4.2.1 Vaccines
       4.2.2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTIs)
       4.2.3 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
       4.2.4 Protease Inhibitors (PIs)
       4.2.5 Viral Fusion (or Entry) Inhibitors
       4.2.6 HIV Integrase Strand Transfer Inhibitors
       4.2.7 CCR5 Receptor Antagonists
   4.3 Market by Geography
       4.1.1 USA
       4.1.2 Europe (EU5)
       4.1.3 Russia & CIS countries
       4.1.4 Brazil
       4.1.5 India
       4.1.6 China
       4.1.7 SouthAfrica
       4.1.8 Turkey
   4.4 Competitive landscape
   4.5 Company profiles
       4.5.1 GlaxoSmithKline
       4.5.2 Abbott Laboratories
       4.5.3 Gilead Sciences
       4.5.4 Bristol-Myers Squibb
       4.5.5 Pfizer

5. Pipeline Analysis
   5.1 Pipeline by Phase
       5.1.1 Lead Optimization/Discovery
       5.1.2 Preclinical
       5.1.3 Phase I
       5.1.4 Phase II
       5.1.5 Phase III
       5.1.6 Pending Approval
       5.1.7 Approved
       5.1.8 Discontinued
   5.2 Molecules by Phase & their profiles
       5.2.1 TMC278
    Investigational Name
    Active Ingredient
    Mechanism of Action
    Dosage form (s)
    Sales forecast
    Expected Launch
(All the above attributes under TMC278 be covered for the
pipeline molecules mentioned below)
       5.2.2 Elvitegravir
       5.2.3 Elvitegravir/GS-9350/Emtricitabine/Tenofovir
       5.2.4 Racivir
       5.2.5 Apricitabine
       5.2.6 Tesamorelin
       5.2.7 MPC 4326
       5.2.8 S/GSK1265744
       5.2.9 UK-453061
       5.2.10 Quad Pill (tenofovir + emtricitabine + elvitegravir + GS 9350)
   5.3 HIV therapeutics Pipeline share by Mechanism of Action (MOA)
       5.3.1 Vaccines
       5.3.2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTIs)
       5.3.3 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
       5.3.4 Protease Inhibitors (PIs)Hemispherx Biopharma
       5.3.5 Viral Fusion (or Entry) Inhibitors
       5.3.6 HIV Integrase Strand Transfer Inhibitors
       5.3.7 CCR5 Receptor Antagonists
       5.3.8 Multi-class Combination Products/ Dual MOA products
   5.4 Competitive Landscape
   5.5 Company Profiles
       5.5.1 GlaxoSmithKline
       5.5.2 Shionogi
       5.5.3 Janssen-Cilag International NV
       5.5.4 VaxGen
       5.5.5 Tibotec Pharmaceuticals
       5.5.6 Merck
       5.5.7 Sanofi-Aventis
       5.5.8 Schering-Plough

Please fill in the form below to receive a free copy of the Summary of this Report

* First Name:

* Last Name:

* Job Title:

* Company:

* Email:

* Phone:

* Country:

  Do you have any Specific field of Interest?
(Our USP is "Customised multi client reports"-so feel free to provide us specific interest in much greater detail..!!)

Reports Interested in ::

Global Human Immunodeficiency Virus (HIV) Market (2012 2017)

  • Select all
  • News-Letters with latest Market insights
  • Information & discussion on the relevant new products and services
  • Information & discussion on Market insights and Market information
  • Information & discussion on our events and conferences
    • Select all
    • Email
    • Phone
    • Professional and social network (Linkedin, etc)
* Enter the text from the image to the textbox :
9 1 7 5 4  

Custom Market Research Services

We will customize the research for you, in case the report listed above does not meet with your exact requirements. Our custom research will comprehensively cover the business information you require to help you arrive at strategic and profitable business decisions.

Please visit https://www.marketsandmarkets.com/knowledge-process-outsourcing-services.asp to specify your custom Research Requirement

Request for FREE Sample of this report Send Request